Association between off-label use of drug-eluting stents and subsequent stent thrombosis: A case-control analysis

Journal of Invasive Cardiology

Volumn 22, Issue 1, 2010, Pages 15-19

  Rabinovitz, Asaf ^a   Bier, Dara M ^b   Wagman, Gabriel M ^a   Charlap, Esti ^b   Nazari, Reza ^c   Ghitelman, Jaime ^c   Celaj, Sulejman ^c   Skeif, Basel ^c   Menegus, Mark ^c   Srinivas, V S ^c  

^a JACOBI MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Drug eluting stent; Off label; Stent thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; FEMALE; GEOGRAPHY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OFF LABEL DRUG USE; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; SIROLIMUS ELUTING STENT; ST SEGMENT; STENT; STENT THROMBOSIS;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OFF-LABEL USE; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIAL CLASS; STENTS;

EID: 76849089127     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
2. Rao SV, Shaw RE, Brindis RG, et al. On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 2006;97:1478-1481.
3. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
4. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-1061.
5. Farb A, Boam AB. Stent thrombosis redux-the FDA perspective. N Engl J Med 2007;356:984-987.
6. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116:1952-1965.
7. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
8. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med 2001;345:99-106.
9. Krieger N, Chen JT, Waterman PD, et al. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: Does the choice of area-based measure and geographic level matter?: The Public Health Disparities Geocoding Project. Am J Epidemiol 2002;156:471-482.
10. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 2006;295:784-792.
11. Singh M, Rihal CS, Selzer F, Kip KE, et al. Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol 2003;42:1722-1728.
12. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009.
13. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000.
14. Applegate RJ, Sacrinty MT, Kutcher MA, et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2008;51:607-614.
15. Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-up of drug-eluting stents when inserted for on-and off-label indications. Am J Cardiol 2007;100:1619-1624.
16. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008;358:342-352.
17. Carlsson J, James S, Lindback J et. al. Outcome of Drug Eluting versus Bare Metal Stenting used according to on or off label crtiteria. J Am Coll of Cardiol 2009;53:1389-1398.
18. Wacholder S, McLaughlin J, Silverman D et al. Selection of Controls in Case control studies. Am J Epidemiol 1992;135:1019-1028.
19. Shishehbor MH, Goel SS, Kapadia SR, et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol 2008;52:1041-1048.
20. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
21. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
22. Applegate RJ, Sacrinty MT, Little WC, et al. Incidence of coronary stent thrombosis based on academic research consortium definitions. Am J Cardiol 2008;102:683-688.